The MHA is at the forefront of advocating for vaccination awareness and education, particularly focusing on the challenges associated with the Beyfortus (nirsevimab) monoclonal antibody for infants entering their first respiratory syncytial virus (RSV) season. The association is actively collaborating with stakeholders to navigate reimbursement and supply concerns. A resolution of these issues is being diligently worked towards, with additional manufacturing and distribution channels being explored. Resources on Beyfortus and other vaccinations can be found on the MHA vaccinations webpage.
Additionally, the MHA, in collaboration with the Michigan Department of Health and Human Services, encourages hospitals and health systems to adopt vaccination policies for healthcare personnel against preventable diseases, especially focusing on COVID-19, influenza and pertussis. There are additional resources on the MHA website for hospitals to assess and improve vaccination protocols.
Members with questions may contact Kelsey Ostergren with the MHA.